198 related articles for article (PubMed ID: 21984210)
1. Structure of an aprataxin-DNA complex with insights into AOA1 neurodegenerative disease.
Tumbale P; Appel CD; Kraehenbuehl R; Robertson PD; Williams JS; Krahn J; Ahel I; Williams RS
Nat Struct Mol Biol; 2011 Oct; 18(11):1189-95. PubMed ID: 21984210
[TBL] [Abstract][Full Text] [Related]
2. Aprataxin resolves adenylated RNA-DNA junctions to maintain genome integrity.
Tumbale P; Williams JS; Schellenberg MJ; Kunkel TA; Williams RS
Nature; 2014 Feb; 506(7486):111-5. PubMed ID: 24362567
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of APTX nicked DNA sensing and pleiotropic inactivation in neurodegenerative disease.
Tumbale P; Schellenberg MJ; Mueller GA; Fairweather E; Watson M; Little JN; Krahn J; Waddell I; London RE; Williams RS
EMBO J; 2018 Jul; 37(14):. PubMed ID: 29934293
[TBL] [Abstract][Full Text] [Related]
4. A novel mutation in the aprataxin (APTX) gene in an Iranian individual suffering early-onset ataxia with oculomotor apraxia type 1(AOA1) disease.
Nouri N; Nouri N; Aryani O; Kamalidehghan B; Sedghi M; Houshmand M
Iran Biomed J; 2012; 16(4):223-5. PubMed ID: 23183622
[TBL] [Abstract][Full Text] [Related]
5. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia/ataxia with oculomotor apraxia 1.
Tada M; Yokoseki A; Sato T; Makifuchi T; Onodera O
Adv Exp Med Biol; 2010; 685():21-33. PubMed ID: 20687492
[TBL] [Abstract][Full Text] [Related]
6. A novel nonsense mutation in the APTX gene associated with delayed DNA single-strand break removal fails to enhance sensitivity to different genotoxic agents.
Crimella C; Cantoni O; Guidarelli A; Vantaggiato C; Martinuzzi A; Fiorani M; Azzolini C; Orso G; Bresolin N; Bassi MT
Hum Mutat; 2011 Apr; 32(4):E2118-33. PubMed ID: 21412945
[TBL] [Abstract][Full Text] [Related]
7. Complex Movement Disorders in Ataxia with Oculomotor Apraxia Type 1: Beyond the Cerebellar Syndrome.
Pedroso JL; Vale TC; da Costa SCG; Santos M; Alonso I; Barsottini OGP
Tremor Other Hyperkinet Mov (N Y); 2020 Oct; 10():39. PubMed ID: 33101765
[TBL] [Abstract][Full Text] [Related]
8. Disease-associated mutations inactivate AMP-lysine hydrolase activity of Aprataxin.
Seidle HF; Bieganowski P; Brenner C
J Biol Chem; 2005 Jun; 280(22):20927-31. PubMed ID: 15790557
[TBL] [Abstract][Full Text] [Related]
9. Aprataxin, causative gene product for EAOH/AOA1, repairs DNA single-strand breaks with damaged 3'-phosphate and 3'-phosphoglycolate ends.
Takahashi T; Tada M; Igarashi S; Koyama A; Date H; Yokoseki A; Shiga A; Yoshida Y; Tsuji S; Nishizawa M; Onodera O
Nucleic Acids Res; 2007; 35(11):3797-809. PubMed ID: 17519253
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterization of ataxia with oculomotor apraxia patients in Saudi Arabia.
Bohlega SA; Shinwari JM; Al Sharif LJ; Khalil DS; Alkhairallah TS; Al Tassan NA
BMC Med Genet; 2011 Feb; 12():27. PubMed ID: 21324166
[TBL] [Abstract][Full Text] [Related]
11. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin.
Moreira MC; Barbot C; Tachi N; Kozuka N; Uchida E; Gibson T; Mendonça P; Costa M; Barros J; Yanagisawa T; Watanabe M; Ikeda Y; Aoki M; Nagata T; Coutinho P; Sequeiros J; Koenig M
Nat Genet; 2001 Oct; 29(2):189-93. PubMed ID: 11586300
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of DNA deadenylation by the neurological disease protein aprataxin.
Rass U; Ahel I; West SC
J Biol Chem; 2008 Dec; 283(49):33994-4001. PubMed ID: 18836178
[TBL] [Abstract][Full Text] [Related]
13. Molecular underpinnings of Aprataxin RNA/DNA deadenylase function and dysfunction in neurological disease.
Schellenberg MJ; Tumbale PP; Williams RS
Prog Biophys Mol Biol; 2015 Mar; 117(2-3):157-165. PubMed ID: 25637650
[TBL] [Abstract][Full Text] [Related]
14. The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4.
Clements PM; Breslin C; Deeks ED; Byrd PJ; Ju L; Bieganowski P; Brenner C; Moreira MC; Taylor AM; Caldecott KW
DNA Repair (Amst); 2004 Nov; 3(11):1493-502. PubMed ID: 15380105
[TBL] [Abstract][Full Text] [Related]
15. Aprataxin, a novel protein that protects against genotoxic stress.
Gueven N; Becherel OJ; Kijas AW; Chen P; Howe O; Rudolph JH; Gatti R; Date H; Onodera O; Taucher-Scholz G; Lavin MF
Hum Mol Genet; 2004 May; 13(10):1081-93. PubMed ID: 15044383
[TBL] [Abstract][Full Text] [Related]
16. Aprataxin, the causative protein for EAOH is a nuclear protein with a potential role as a DNA repair protein.
Sano Y; Date H; Igarashi S; Onodera O; Oyake M; Takahashi T; Hayashi S; Morimatsu M; Takahashi H; Makifuchi T; Fukuhara N; Tsuji S
Ann Neurol; 2004 Feb; 55(2):241-9. PubMed ID: 14755728
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation of aprataxin associated with ataxia ocular apraxia type 1: phenotypical and genotypical characterization.
Ferrarini M; Squintani G; Cavallaro T; Ferrari S; Rizzuto N; Fabrizi GM
J Neurol Sci; 2007 Sep; 260(1-2):219-24. PubMed ID: 17572444
[TBL] [Abstract][Full Text] [Related]
18. The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates.
Ahel I; Rass U; El-Khamisy SF; Katyal S; Clements PM; McKinnon PJ; Caldecott KW; West SC
Nature; 2006 Oct; 443(7112):713-6. PubMed ID: 16964241
[TBL] [Abstract][Full Text] [Related]
19. Ataxia with Ocular Apraxia Type 1 (AOA1) (APTX, W279* Mutation): Neurological, Neuropsychological, and Molecular Outlining of a Heterogenous Phenotype in Four Colombian Siblings.
Aguillon D; Vasquez D; Madrigal L; Moreno S; Hernández D; Isaza-Ruget M; Lopez JJ; Landires I; Nuñez-Samudio V; Restrepo CM; Vidal OM; Vélez JI; Arcos-Holzinger M; Lopera F; Arcos-Burgos M
Mol Neurobiol; 2022 Jun; 59(6):3845-3858. PubMed ID: 35420381
[TBL] [Abstract][Full Text] [Related]
20. [Ataxia with oculomotor apraxia: clinical-genetic characteristics and DNA-diagnostic].
Rudenskaia GE; Kurkina MV; Zakharova EIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10):58-63. PubMed ID: 23250602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
